secwatch.observer — SEC 8-K summary
======================================

Issuer:     IO Biotech, Inc. (IOBTQ)
CIK:        0001865494
Form:       8-K
Filed at:   2023-07-18T23:59:59+00:00
Accession:  0001193125-23-188851
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IO Biotech appoints Qasim Ahmad as CMO, promotes Eric Faulkner to CTO
---------------------------------------------------------------------

- Qasim Ahmad, MD, appointed CMO effective July 15; previously Novartis SVP, US Head Clinical Development & Medical Affairs.
- Eva Ehrnrooth transitions from CMO to Senior Clinical Advisor; departure not due to any disagreement.
- Eric Faulkner promoted to CTO; previously Sr. VP CMC, will oversee CMC and Quality for commercial readiness.
- Ahmad granted inducement option for 288,153 shares vesting over 4 years (25% cliff at year one).
- Changes position company for BLA filing and next stage of growth; Ahmad based in US.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1865494/000119312523188851/0001193125-23-188851-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1865494/000119312523188851/d523717d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-188851

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer